| 000 | 01087 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250516203333.0 | ||
| 264 | 0 | _c20140602 | |
| 008 | 201406s 0 0 eng d | ||
| 022 | _a1474-4465 | ||
| 024 | 7 |
_a10.1016/S1474-4422(14)70056-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBarkhof, Frederik | |
| 245 | 0 | 0 |
_aDaclizumab in multiple sclerosis: a high-yield extension study. _h[electronic resource] |
| 260 |
_bThe Lancet. Neurology _cMay 2014 |
||
| 300 |
_a443-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 | _aDaclizumab |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xtherapeutic use |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 700 | 1 | _aCiccarelli, Olga | |
| 773 | 0 |
_tThe Lancet. Neurology _gvol. 13 _gno. 5 _gp. 443-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1474-4422(14)70056-0 _zAvailable from publisher's website |
| 999 |
_c23664868 _d23664868 |
||